FDA lifts clinical hold on Filana's simufilam, clearing path for TSC epilepsy study
Filana Therapeutics said patient screening for a Phase 2a trial in TSC-related epilepsy is expected to begin by the first quarter of 2027.
SEC filing
Latest
2 stories
Tuesday, September 22
Wednesday, July 29
Filana Therapeutics still under FDA clinical hold on simufilam trial, reports Q2 2026 results
The company said it continues to work with the FDA to resolve the hold as it heads into the TSC World Conference, while cash fell to $82.7 million.
SEC filing